CoImmune, Inc. announced Thursday that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, in advanced renal cell carcinoma. With the merger’s completion, CoImmune will use the newly acquired technology, CAR-CIK (cytokine-induced killer cells), for clinical development in acute lymphoblastic leukemia.
Read the full article: CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc. //
Source: https://www.globenewswire.com/news-release/2020/04/30/2025689/0/en/CoImmune-Inc-a-US-Based-Clinical-Stage-Biotech-Completes-Merger-with-Formula-Pharmaceuticals-Inc.html